CoChat

GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials

Kapoor, Ishani, Sarvepalli, Swara M., D’Alessio, David, Grewal, Dilraj S., Hadziahmetovic, Majda · 2023 · Survey of Ophthalmology
Cited by 81

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are used to treat type 2 diabetes mellitus. Recent research suggests GLP-1 RAs may influence diabetic retinopathy (DR). We searched ClinicalTrials.gov for trials comparing FDA-approved GLP-1 RAs to placebo, insulin, or oral antidiabetic medicine. Rates of DR, ocular adverse events (AEs), demographics, and clinical characteristics were compared amongst cohorts on 93 trials. GLP-1 RA use was significantly associated with increased risk of early-stage DR (RR = 1.31, 95% CI [1.01, 1.68]) and early-stage retinal AEs (RR = 1.29, 95% CI [1.01, 1.66]) compared to placebo. Compared to insulin, GLP-1 RA use protected against late-stage DR (RR = 0.38, 95% CI [0.15, 0.98]). Analysis of individual GLP-1 RAs showed albiglutide is responsible for these trends, as it is significantly associated with a higher risk of early-stage DR (RR = 2.18, 95% CI [1.01, 4.67]) compared to placebo and a lower risk of late-stage DR (RR = 0.25, 95% CI [0.09, 0.70]) compared to insulin. Albiglutide similarly affected retinal and ocular AEs. Demographic analysis revealed significant differences between GLP-1 RA and comparator groups for age, HbA1c, body weight, BMI, duration of diabetes, sex, race, and ethnicity. The influence of GLP-1 RAs on DR and the eye may depend on the specific GLP-1 RA and patient demographic and clinical characteristics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.survophthal.2023.07.002

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 5

  1. Simó, 2017, GLP-1R as a target for the treatment of diabetic retinopathy: Friend or foe?, Diabetes, 66, 1453, 10.2337/db16-1364 · DOI · Paper page
  2. Wang, 2022, Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials, Clin Drug Investig, 42, 17, 10.1007/s40261-021-01110-w · DOI
  3. Bain, 2019, Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review, Diabetes Obes Metab, 21, 454, 10.1111/dom.13538 · DOI · Paper page
  4. Chudleigh, 2020, Comparative effectiveness of long-acting GLP-1 receptor agonists in type 2 diabetes: A short review on the emerging data, Diabetes Metab Syndr Obes Targets Ther, 13, 433, 10.2147/DMSO.S193693 · DOI
  5. Rose, 2020, Real-world impact on monthly glucose-lowering medication cost, HbA1c, weight, and polytherapy after initiating a GLP-1 receptor agonist, J Am Pharm Assoc, 60, 31, 10.1016/j.japh.2019.09.001 · DOI

Cited by

See all 81

Metadata

Authors
Kapoor, I., Sarvepalli, S. M., D’Alessio, D., Grewal, D. S., & Hadziahmetovic, M.
Venue
Survey of Ophthalmology
Publisher
Elsevier BV
Published
2023-11
Volume
68
Issue
6
Pages
1071-1083
ISSN
0039-6257 (ISSN-L)
OpenAlex
W4384469967
Cited by
81
References
11
FWCI
4.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. https://app.cochat.ai/papers/10.1016/j.survophthal.2023.07.002
The paper
Kapoor, I., Sarvepalli, S. M., D’Alessio, D., Grewal, D. S., & Hadziahmetovic, M. (2023). GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Survey of Ophthalmology. https://doi.org/10.1016/j.survophthal.2023.07.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.